bioRxivCancer BiologyPreprint
Fibroblast-Enhanced Tumour Microenvironment Signalling Promotes Adaptive Doxorubicin Tolerance in Heterotypic Melanoma Spheroids
I PaveliD, Giorgiana NegreaiD, Marta Szilvia MeszarosiD, Valentin Florian RaucaiD, Bogdan Razvan Dume, Emilia LicăreteiD, Laura PătrașiD, Stefan DraganiD, Vlad Alexandru TomaiD, Alina SesărmaniD, Manuela BanciuiD
Abstract
Melanoma is an aggressive malignancy that rapidly adapts to therapy. While chemotherapy resistance has traditionally been attributed to tumour-intrinsic mechanisms, growing evidence implicates the tumour microenvironment in shaping drug tolerance. However, few in vitro models capture the stromal complexity needed to study this interaction. We developed two multicellular melanoma spheroid models of increasing stromal complexity: a baseline model of melanoma, endothelial, and macrophage cells (BEM), and a fibroblast-containing counterpart (BEMF), and compared their transcriptional response to doxorubicin. Fibroblast inclusion increased the doxorubicin concentration required to achieve comparable growth inhibition. While untreated BEMF spheroids exhibited only modest baseline transcriptional differences, they showed a profoundly reshaped transcriptional response after doxorubicin exposure, displaying broader and higher-magnitude changes. These responses were characterized by suppression of proliferative and cell-cycle programmes, together with activation of inflammatory, immune-associated, metabolic, and stress-adaptive pathways. Higher-resolution pathway analyses further revealed coordinated attenuation of mitotic progression, checkpoint regulation, homologous recombination repair, and Rho GTPase signalling, consistent with a shift toward stress-adaptive and phenotypically plastic states, rather than classical resistance mechanisms. Transcriptome-derived transcription factor activity inference supported this regulatory rewiring. Integration with curated resistance-associated genes and external transcriptomic datasets demonstrated strong conservation of core transcriptional features across heterogeneous experimental systems, including consistent suppression of proliferation-associated genes and induction of inflammatory signalling programmes. Together, these findings indicate that fibroblasts redirect chemotherapy responses toward a stress-adaptive, persister-like phenotype and establish fibroblast-containing 3D melanoma spheroids as a physiologically relevant platform for studying tumour microenvironment-mediated chemotherapy tolerance and stromal-tumour interactions.
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: statistical model
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Exploring the mechanisms of early acquired resistance to doxorubicin in melanoma spheroids
Giorgiana Negrea, Ilie Ovidiu Pavel, … Alina Sesărman·bioRxiv·Apr 7, 2025
- Spatial transcriptomics reveals influence of microenvironment on intrinsic fates in melanoma therapy resistance
Ryan H. Boe, Catherine G. Triandafillou, … Arjun Raj·Genome biologyPeer-reviewed·Apr 30, 2026
- Fibroblasts from metastatic sites induce broad-spectrum drug desensitization via modulation of mitochondrial priming
B. D. Landry, T. Leete, … M. J. Lee·bioRxiv·Oct 2, 2017
- Human fibrosarcoma cells selected for very-high doxorubicin resistance, acquire trabectedin and eribulin cross-resistance, remain sensitive to recombinant methioninase, and have increased c-MYC expression
Sei Morinaga, Qinghong Han, … Robert M. Hoffman·Frontiers in OncologyPeer-reviewed·Dec 8, 2025
- Volumetric mechanoplasticity couples melanoma drug tolerance to susceptibility to CD8+ T cell killing
Xingjian Zhang, Dingyao Zhang, … Michael Mak·bioRxiv·Jan 30, 2026
- Cancer cell adaptations along a proliferation-robustness axis drive TME pro-tumor phenotypes
Maayan Pour, Guisheng Zhao, … Itai Yanai·bioRxiv·Oct 29, 2026